{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:04:20Z","timestamp":1790125460153,"version":"4.0.1"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020357","name":"Amneal Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020357","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","prd-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.parkreldis.2024.107239","type":"journal-article","created":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T15:10:12Z","timestamp":1734275412000},"page":"107239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Duration of \u201cGood On\u201d time per dose: Immediate-release carbidopa-levodopa vs. extended-release carbidopa-levodopa (IPX203, CREXONT\u00ae)"],"prefix":"10.1016","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6369-1203","authenticated-orcid":false,"given":"R.A.","family":"Hauser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.H.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9772-7569","authenticated-orcid":false,"given":"J.","family":"Jimenez-Shahed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Allard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Banisadr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"D'Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.parkreldis.2024.107239_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000215875","article-title":"Levodopa: past, present, and future","volume":"62","author":"Hauser","year":"2009","journal-title":"Eur. Neurol."},{"issue":"1","key":"10.1016\/j.parkreldis.2024.107239_bib2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/mds.26078","article-title":"Novel formulations and modes of delivery of levodopa","volume":"30","author":"Poewe","year":"2015","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.parkreldis.2024.107239_bib3","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/mds.26082","article-title":"Levodopa therapy for Parkinson's disease: pharmacokinetics and pharmacodynamics","volume":"30","author":"LeWitt","year":"2015","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.parkreldis.2024.107239_bib4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1602\/neurorx.1.1.139","article-title":"Neurodegeneration and neuroprotection in Parkinson disease","volume":"1","author":"Fahn","year":"2004","journal-title":"NeuroRx"},{"issue":"3","key":"10.1016\/j.parkreldis.2024.107239_bib5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3233\/JPD-130186","article-title":"Levodopa in the treatment of Parkinson's disease: current status and new developments","volume":"3","author":"Salat","year":"2013","journal-title":"J. Parkinsons Dis."},{"issue":"1","key":"10.1016\/j.parkreldis.2024.107239_bib6","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/mds.26125","article-title":"Clinical spectrum of levodopa-induced complications","volume":"30","author":"Aquino","year":"2015","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.parkreldis.2024.107239_bib7","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2165\/00023210-200721080-00005","article-title":"Medical management of levodopa-associated motor complications in patients with Parkinson's disease","volume":"21","author":"Jankovic","year":"2007","journal-title":"CNS Drugs"},{"issue":"12","key":"10.1016\/j.parkreldis.2024.107239_bib8","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1111\/ene.13466","article-title":"L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey","volume":"24","author":"Perez-Lloret","year":"2017","journal-title":"Eur. J. Neurol. : Offi. J European Federa. Neurol. Soc."},{"issue":"8","key":"10.1016\/j.parkreldis.2024.107239_bib9","article-title":"Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation","volume":"24","author":"LeWitt","year":"2023","journal-title":"Clin. Park Relat Disord."},{"issue":"10","key":"10.1016\/j.parkreldis.2024.107239_bib10","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jamaneurol.2023.2679","article-title":"Efficacy and safety of IPX203 (carbidopa-levodopa extended-release formulation) in Parkinson's disease patients with motor fluctuations (RISE-PD)","volume":"80","author":"Hauser","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.parkreldis.2024.107239_bib11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.parkreldis.2020.12.002","article-title":"Duration of benefit per Dose: carbidopa-Levodopa immediate release vs. extended release capsules (Rytary\u00ae)","volume":"82","author":"Hauser","year":"2021","journal-title":"Park. Relat. Disord."},{"issue":"2","key":"10.1016\/j.parkreldis.2024.107239_bib12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00702-003-0092-9","article-title":"Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa\/carbidopa in Parkinson's patients","volume":"111","author":"Stocchi","year":"2004","journal-title":"J. Neural. Transm."},{"issue":"1","key":"10.1016\/j.parkreldis.2024.107239_bib13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00002826-200401000-00008","article-title":"Effect of riluzole on dyskinesia and duration of the on state in Parkinson disease patients: a double-blind, placebo-controlled pilot study","volume":"27","author":"Braz","year":"2004","journal-title":"Clin. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.parkreldis.2024.107239_bib14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/WNF.0000000000000314","article-title":"Single-dose pharmacokinetics and pharmacodynamics of IPX203 in patients with advanced Parkinson disease: a comparison with immediate-release carbidopa-levodopa and with extended-release carbidopa-levodopa capsules","volume":"42","author":"Modi","year":"2019","journal-title":"Clin. Neuropharmacol."}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802024012513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802024012513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T11:11:32Z","timestamp":1737630692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802024012513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":14,"alternative-id":["S1353802024012513"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2024.107239","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Duration of \u201cGood On\u201d time per dose: Immediate-release carbidopa-levodopa vs. extended-release carbidopa-levodopa (IPX203, CREXONT\u00ae)","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2024.107239","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107239"}}